T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2026

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG

Trastuzumab Deruxtecan

Trastuzumab Deruxtecan for TNBC-LAR patients with HER2 low expression

Trial Locations (1)

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT05953168 - T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | Biotech Hunter | Biotech Hunter